Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
1.290
+0.120 (10.26%)
At close: Jun 26, 2026, 4:00 PM EDT
1.260
-0.030 (-2.33%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Company Description
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.
The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand.
Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Dermata Therapeutics, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Aug 13, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Gerald Proehl |
Contact Details
Address: 3525 Del Mar Heights Rd., Suite 332 San Diego, California 92130 United States | |
| Phone | 858 800 2543 |
| Website | dermatarx.com |
Stock Details
| Ticker Symbol | DRMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 0001853816 |
| CUSIP Number | 249845504 |
| ISIN Number | US2498455045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gerald T. Proehl | Founder, President, Chief Executive Officer and Chairman |
| David F. Hale | Co-Founder and Lead Independent Director |
| Kyri K. Van Hoose CPA, M.B.A. | Senior Vice President and Chief Financial Officer |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Senior Vice President and Chief Development Officer |
| Sean Proehl | Associate General Counsel |
| Kyra Peckaitis | Vice President of Marketing |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 4, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 1, 2026 | SCHEDULE 13D | Filing |
| May 29, 2026 | EFFECT | Notice of Effectiveness |
| May 29, 2026 | 424B3 | Prospectus |
| May 27, 2026 | 8-K | Current Report |
| May 22, 2026 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| May 13, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | 8-K | Current Report |
| Apr 22, 2026 | SCHEDULE 13G/A | Filing |